Retatrutide at Low Dose: Why the Research Case for Less Is Stronger

Vendor protocols routinely recommend escalating to 6-8mg. This piece examines why the research-aligned approach caps at 2.5mg — with comparable outcomes and meaningfully lower receptor stress.